The goal of this research is to determine if DetectnetTM PET/CT can be used to make Lutathera therapy safer for patients with neuroendocrine cancer.
Participants will:
* Complete two phases involving 6 visits
* Undergo additional research PET/CT, and possibly SPECT/CT scans

Start Date07 Mar 2025

Sponsor / Collaborator

University of Wisconsin Madison

NCT04529044

/ Not yet recruitingPhase 2IIT

A Phase II Pilot Study of (Lutetium (177Lu)-DOTATATE in Patients with Metastatic Breast Cancer

This phase II trial investigates how well 177Lu-DOTATATE works in treating patients with breast cancer that is stage IV or has come back (recurrent). 177Lu-DOTATATE may shrink or destroy the tumor or circulating breast cancer stem cells if they show evidence of the SSTR2. 177Lu-DOTATATE is a targeted therapy that uses DOTATATE, linked to a radioactive agent called 177Lu. DOTATATE attaches to tumor cells with SSTR2 and delivers 177Lu to kill them. Giving 177Lu-DOTATATE may help decrease the number and size of tumors and the number of circulating cancer stem cells in patient's blood for the treatment of patients with breast cancer positive for SSTR2.

Start Date01 Jan 2025

Sponsor / Collaborator

OHSU Knight Cancer Institute

[+3]

NCT06663072

/ RecruitingPhase 1IIT

A Phase I Study of Fulvestrant in Combination With Lu-DOTATATE for Advanced Pancreatic Neuroendocrine Tumors

This is a phase I, open-label study to assess the safety and preliminary efficacy of Fulvestrant in combination with 177Lu-DOTATATE for advanced pNETs.

Start Date13 Dec 2024

Sponsor / Collaborator

The University of Chicago

100 Clinical Results associated with Lutetium Dotatate LU-177

100 Translational Medicine associated with Lutetium Dotatate LU-177

100 Patents (Medical) associated with Lutetium Dotatate LU-177

976

Literatures (Medical) associated with Lutetium Dotatate LU-177

01 Mar 2025·JOURNAL OF NUCLEAR MEDICINE

Dosimetry of [¹⁷⁷Lu]Lu-DOTATATE in Patients with Advanced Midgut Neuroendocrine Tumors: Results from a Substudy of the Phase III NETTER-1 Trial

Article

Author: Gericke, Germo ; Chicco, Daniela ; Mittra, Erik S ; Cremonesi, Marta ; Srirajaskanthan, Rajaventhan ; Kulkarni, Harshad R ; Demange, Arnaud ; Mariani, Maurizio F ; Ferrari, Mahila ; Krenning, Eric ; Grana, Chiara Maria ; Botta, Francesca ; Miederer, Matthias ; Erion, Jack L ; Ramage, John ; Bodei, Lisa ; Weber, Matthias M ; Reddy, Ryan ; Deroose, Christophe M

This substudy of the phase III NETTER-1 trial evaluated [¹⁷⁷Lu]Lu-DOTATATE (hereafter ¹⁷⁷Lu-DOTATATE) for advanced midgut neuroendocrine tumors and aimed to assess dosimetry of a standard 4-cycle protocol and any potential relationship to toxicity. Change in tumor size by absorbed dose was an exploratory endpoint. Methods: Patients with locally advanced or metastatic, well-differentiated, midgut neuroendocrine tumors were enrolled in this substudy between August 2013 and January 2016. Patients were scheduled to receive 4 infusions of 7.4 GBq of ¹⁷⁷Lu-DOTATATE for a cumulative injected activity of 29.6 GBq. After a ¹⁷⁷Lu-DOTATATE infusion, whole-body planar images (4-6 time points for up to 7 d) and SPECT/CT images (at 24 and/or 48 h) were acquired, and absorbed and time-integrated activity coefficients were calculated to derive dosimetry. Blood and urine samples were used to determine the blood clearance and activity elimination rate. Tumor absorbed dose was derived using a sphere model, interpolating ¹⁷⁷Lu dose factors on the basis of each lesion mass. Tumor size was assessed by measuring the longest and perpendicular dimensions on CT at measured time points. Results: Dosimetric assessments were evaluated in 20 patients. Organ dosimetry showed substantial interpatient variability. The predicted mean cumulative absorbed doses to kidneys and bone marrow were 19.4 (SD, 8.7) and 1.0 (SD, 0.8) Gy, respectively. Three patients had kidney doses between 28 and 33 Gy; 2 had grade 1 increased serum creatinine, and 1 showed no evidence of renal toxicity (up to 5 y of follow-up). Hematologic toxicity was primarily mild or moderate (grade 1-2) with no increase over time or association with cumulative absorbed dose. Tumor kinetics in 65 lesions demonstrated stable activity over time. Inter- and intrapatient variability was observed, and the median cumulative absorbed dose was 134 Gy (range, 7-2,218 Gy). Acknowledging the limitations of the imaging methods used and tumor volume assessments, we found no correlation between the best tumor size reduction and the absorbed dose, though most tumors (90%) shrank over the 72-wk study period. Conclusion: The dosimetry data support the findings that the standard treatment regimen with ¹⁷⁷Lu-DOTATATE that includes personalized adjustments according to acute toxicity assessments is well tolerated and manageable.

01 Mar 2025·Practical Radiation Oncology

Unplanned Emergency Department or Inpatient Acute Care Within 1 Week After Administration of Peptide Receptor Radionuclide Therapy: Frequency of Occurrence and Standard Operating Procedures for Radioprotection in These Situations

Article

Author: Huffstetler, Courtney E ; Franklin, Elizabeth ; Prabhu, Roshan S ; Rowland, Chelsea L ; McBride, James E ; Russek, Rachel ; Price, Karen B ; Garland, Danielle N ; Ward, Matthew C ; McHaffie, Derek R ; Hicks, Amy S

Peptide receptor radionuclide therapy (PRRT) is a rapidly developing treatment modality. These treatments are indicated for patients who are either heavily pretreated and/or may have neurohormonal active disease, increasing the risk of acute adverse effects and the need for unplanned acute care. The goals of this report were to characterize the frequency of unplanned acute care utilization after PRRT infusion and detail a comprehensive standard operating procedure (SOP) for radioprotection during unplanned post-PRRT acute care. The records of patients treated with PRRT were reviewed. The event of interest was emergency department (ED) utilization and/or inpatient admission within 7 days of PRRT infusion. A multidisciplinary group developed a radioprotection SOP for all phases of unplanned acute care including the clinical infusion space and emergency medical services transport to the ED, within the ED, and on the inpatient floor. A total of 232 patients received 814 infusions of PRRT, with 134 (58%) receiving Lutathera and 98 (42%) receiving Pluvicto. Nineteen patients received unplanned acute care at an ED within 7 days of PRRT infusion (8% of patients, 2% of infusions), of which 10 received Lutathera (8% of patients, 2% of infusions). Two patients (2% of patients, 0.5% of infusions) experienced carcinoid crises within 24 hours of Lutathera infusion. The median and average intervals between infusion and ED visit were 0.5 days and 1.3 days, respectively. Nine patients received Pluvicto (9% of patients, 3% of infusions). The median and average intervals between infusion and ED visit were 4 and 4.7 days, respectively. Emergency room utilization and/or inpatient admission after PRRT administration are relatively infrequent events, but not unexpected. Centers that administer PRRT should have a comprehensive SOP in place to effectively care for radioactive patient emergencies while maximizing medical staff protection.

01 Mar 2025·JOURNAL OF RADIOLOGICAL PROTECTION

Harmonization of practice of release of patients after radiopharmaceutical therapy

Article

Author: Vodovatov, Aleksandr ; Chipiga, Larisa ; Vazhenina, Daria ; Stanzhevskiy, Andrey ; Likhacheva, Anastasia ; Maystrenko, Dmitrii ; Zvonova, Irina

Abstract:

The implementation of novel therapeutic radiopharmaceuticals requires developing, updating, and harmonizing requirements for radiation safety in radiopharmaceutical therapy (RPT). Public exposure from patients with administered radiopharmaceuticals and biological radioactive waste management have been identified as the main problems in RPT. The aim of our study was to compare different approaches to the development of patient release criteria after RPT with different radiopharmaceuticals, considering radiation exposure of members of the public in transport, biological elimination of radionuclides from a patient’s body, and the generation of biological waste. The study was performed for the following radiopharmaceuticals: 177Lu-PSMA-617, 177Lu-DOTATATE, Na131I, 131I-mIBG, and 153Sm-oxabifor. Two base approaches to patient release criteria were considered. The first approach is based on the radioactive decay of radionuclides and is divided into two groups: considering one radiopharmaceutical administration and considering several radiopharmaceutical administrations per course. The second approach is based on the radioactive decay of radionuclides and biological elimination of radiopharmaceuticals from the patient’s body (effective half-life) and is divided into groups based on 1 and 5 mSv dose constraints per course. The ffective dose rates from patients and sewage tanks to passengers and staff on public transport were estimated for various scenarios of patients traveling after RPT. The results demonstrated that the radiation safety of members of the public in transport should be considered when establishing the release criteria of patients after RPT. Based on the results, it is recommended to follow the approach based on the radioactive decay of radionuclides and dose constraints to members of the public in contact with patients of 1 mSv per radiopharmaceutical administration, and keep patients in the nuclear medicine department after radiopharmaceutical administration for at least 4–6 h. The patient release criteria defined according to this approach comply with patient release criteria used in different countries, and allow the radiation safety of the public to be maintained.

253

News (Medical) associated with Lutetium Dotatate LU-177

28 Mar 2025

·www.globenewswire.com

Curium Completes the Acquisition of Monrol as Part of its Plan to Significantly Expand Lutetium-177 Capacity and PET Footprint

Positions Curium as leading manufacturer of Lu-177 isotopeBrings innovative R&D expertise and pipeline to Curium Enhances Curium’s SPECT & PET geographical coverage and supply chain PARIS, March 28, 2025 (GLOBE NEWSWIRE) -- Curium Pharma (“Curium”), a world leader in nuclear medicine, is pleased to announce the completion of its acquisition of Eczacıbaşı-Monrol Nuclear Products Co. (Monrol), a leading nuclear medicine player, which is headquartered in Istanbul, Turkey. The acquisition enhances Curium’s manufacturing capacity of Lutetium-177 (Lu-177) to meet the growing demand for isotope around the world and secure the supply for the future launch of Curium’s Lu-177 drug candidates, for Prostate Cancer (currently in development) and Neuroendocrine Tumours (pending approval). Monrol complements and adds to Curium’s extensive research & development (R&D) capabilities as it continues to expand its portfolio and pipeline of innovative theranostic products. Curium intends to deploy Monrol’s Ga-68 generator globally in the future, pending regulatory approvals. In addition, Monrol’s PET & SPECT complementary geographic footprint further expands Curium’s offering. The completion of the deal expands Curium’s PET footprint of 34 sites in Western Europe and Asia to 46 with the addition of 12 Monrol owned and partnered sites in Eastern Europe and MENA regions. Furthermore, Monrol’s manufacturing and logistics infrastructure in Istanbul, Turkey, immediately adds scale to Curium’s vertically integrated production and distribution capabilities. Mr. Chaitanya Tatineni, Curium’s CEO International Markets commented: “We are delighted to welcome close to 400 highly-skilled and dedicated new colleagues to Curium Group. The coming together of Curium and Monrol will transform our scale, capabilities and reach across several critical areas, in particular Lu-177, and create multiple new opportunities to enhance our offering of life-changing diagnostic and therapeutic solutions to patients around the world.” Mr. Aydin Kucuk General Manager at Monrol added: “We are excited to be joining Curium and have long admired the company’s capabilities, leadership and commitment to developing and supplying world-class nuclear diagnostics solutions and therapies. We look forward to working with our new Curium colleagues to build on our joint successes to date by integrating our expertise, knowledge and experience with Curium’s global footprint, product portfolio, and track record of innovation.” Mr. Emin Fadıllıoğlu, CEO, Eczacıbaşı Pharmaceutical and Industrial Investment, said: “We are very proud of our association with Monrol and its transformation in recent years, which today sees them become part of Curium, a world-leader in nuclear medicine. This is a great reflection of the quality of the business, and we believe they will continue to thrive under the ownership of Curium, benefiting from greater access to advanced technology and an extensive global network.” For more information: communications@curiumpharma.com or Ben ValdimarssonReputation IncMob: +44 (0)788 9805930Email: bvaldimarsson@reputation-inc.com About CuriumCurium is a world leader in nuclear medicine. We develop, manufacture, and distribute world-class radiopharmaceutical products to help patients around the globe. Our proven heritage combined with a pioneering approach are the hallmarks to deliver innovation, excellence, and unparalleled service. With manufacturing facilities across Europe and the United States, Curium delivers SPECT, PET and therapeutic radiopharmaceutical solutions for life-threatening diseases to over 14 million patients annually. The name ‘Curium’ honors the legacy of pioneering radioactive materials researchers Marie and Pierre Curie, after whom the radioactive element curium was named and emphasizes our focus on nuclear medicine. To learn more, visit www.curiumpharma.com About MonrolHeadquartered in Istanbul, Monrol is a nuclear medicine company leading innovation for the development and manufacturing of GMP grade radioisotopes and radiopharmaceuticals, Monrol distributes its world-class radiopharmaceutical products portfolio in global markets. As both a CMO and CDMO, Monrol provides early development support to customers and offers fully integrated services for nimble, lean, virtual companies taking new product concepts into clinical trials, demonstrating proof of concept, and going into first-in-human studies. Monrol is committed to transform and improve patient journey in cancer treatment through a portfolio of radiopharmaceutical products that it distributes to more than 60 countries around the globe. To learn more, visit www.monrol.com.

AcquisitionRadiation Therapy

06 Mar 2025

·firstwordpharma.com

ITM fleshes out data for Phase III radiopharma success in neuroendocrine tumours

A radiopharmaceutical from ITM Isotope Technologies Munich reduced the risk of disease progression or death by 33% versus Novartis' targeted molecular therapy Afinitor (everolimus) in patients with gastroenteropancreatic neuroendocrine tumours (GEP-NETs). The outcome of the Phase III COMPETE study was first top-lined in January, with the announcement marking one of only a handful of wins for a radiopharmaceutical in a head-to-head trial. Detailed results were presented Thursday at the European Neuroendocrine Tumor Society (ENETS) annual meeting.The trial compared ITM-11 (177Lu-edotreotide) with Afinitor in 309 patients with inoperable, progressive Grade 1 or 2 somatostatin receptor (SSTR)-positive GEP-NETs. According to ITM, approximately 15% of people in each trial arm were treatment naïve, with the remaining 85% or so having received one prior therapy.Results showed that median progression-free survival (PFS) for ITM's therapeutic was 23.9 months, which was significantly and clinically better than the 14.1 months for Afinitor. In comparison, in the Phase III NETTER-2 trial, Novartis' peptide receptor radionuclide therapy Lutathera (lutetium Lu 177 dotatate) reduced the risk of disease progression or death by 72% as a first-line therapy for patients with SSTR-positive well-differentiated Grade 2/3 advanced GEP-NETs versus high-dose octreotide LAR alone, with median PFS in the two arms of 22.8 months and 8.5 months, respectively.ITM told FirstWord that the choice of Afinitor as a comparator in COMPETE was "backed by scientific evidence of efficacy and high clinical acceptance after market authorisation." The company suggested that this decision set "a higher standard for meeting the primary endpoint in more advanced grade tumours," adding that it hopes "physicians will recognise the higher threshold of our study design."FDA filing this year"These successful results validate our decision to design a pivotal Phase III trial directly comparing a targeted radiopharmaceutical against a targeted molecular therapy," CEO Andrew Carey said. Based on the findings, ITM plans to seek approval of ITM-11 in the US this year; however, the company told FirstWord that it is "currently prohibited" from filing in Europe until 2029 due to orphan drug designation on Lutathera.Top-line results also showed that interim median overall survival (OS) was 63.4 months for ITM-11. That was numerically higher than the 58.7 months seen with Afinitor, but not statistically significant at the current analysis. ITM noted that patients were allowed to start an alternative therapy after disease progression, "potentially confounding" the OS data."These data show unequivocal support for [ITM-11's] potential benefit in extending PFS," remarked study investigator Jaume Capdevila, adding that the radiopharmaceutical's "convenient dosing schedule and favourable safety results reinforce its potential as a compelling new treatment option."In COMPETE, patients were treated with ITM-11 every three months for up to four cycles, or with Afinitor daily for up to 30 months, or until disease progression. Meanwhile, ITM's therapy was well tolerated, with treatment-emergent adverse events occurring at a rate of 82.5%, compared with 97% for Afinitor. However, there was one Grade 2 event of myelodysplastic syndrome in the ITM-11 arm.Growing optionsNeuroendocrine tumours are one of the few cancers that have so far benefited from the approval of radiopharmaceuticals. Novartis currently markets Lutathera as a treatment for SSTR-positive GEP-NETs, while Sanofi also has skin in the game, having reached a deal last year to join forces with RadioMedix and Orano Med on the radioligand medicine AlphaMedix (212Pb-DOTAMTATE).Something that differentiates ITM from other players, however, is that it has worked in the radiopharma space for over 20 years and has manufacturing in-house. "Together, with our global isotopes manufacturing business, robust supply chain and experienced clinical and commercial team, we believe we are uniquely positioned as a standout leader in the fast-growing radiopharmaceutical industry," Carey said.ITM-11 — which combines the therapeutic β-emitting radioisotope lutetium-177 with the synthetic SSTR agonist edotreotide — is also being investigated in the Phase III COMPOSE trial in patients with well-differentiated, aggressive Grade 2 or 3 SSTR-positive GEP-NETs.

Phase 3Clinical ResultOligonucleotideOrphan Drug

06 Mar 2025

·endpts.com

ITM reports more Phase 3 radiopharma data in challenge to Novartis’ Lutathera

ITM Isotope Technologies Munich’s radiopharma candidate reduced neuroendocrine tumor patients’ risk of progression or death by a third compared with standard therapy, according to pivotal data presented Thursday. The figure is statistically significant but is also lower than what was seen with Novartis’ radioligand Lutathera in its registrational trial in the same disease. That is not a problem, ITM’s CEO Andrew Cavey told Endpoints News , since the trials used different control arms. “We hopefully will be able to show clinicians that we picked a higher bar of clinical care, and we are able to beat that higher bar,” Cavey said. ITM’s COMPETE trial, in patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs), pitted its lutetium-177-based radioligand ITM-11 against the targeted therapy everolimus. The German biotech declared victory in January , but now more detailed data show that the median PFS was 23.9 months with ITM-11 versus 14.1 months on everolimus. The NETTER-1 trial of Lutathera showed a risk reduction of 79% on progression-free survival but against the somatostatin analog octreotide, rather than everolimus. A lower dose of octreotide was given in the Lutathera arm too, another difference from ITM’s study. The populations in the two trials were also different. COMPETE enrolled patients with pancreatic GEP-NETs as well as those with midgut tumors. Patients with pancreatic tumors have a worse prognosis and were excluded from Novartis’ study. Dosing is also slightly more convenient, at every three months versus every two months for Lutathera. Interim median overall survival in the COMPETE study was 63.4 months in the ITM-11 arm and 58.7 months with control as of Jan. 21. This was not statistically significant, but the pivotal trial of Lutathera also failed to hit significance at its final OS analysis, which occurred 66 months after the primary PFS analysis. ITM’s data were presented at the European Neuroendocrine Tumor Society conference, held in Krakow, Poland. ITM intends to take the COMPETE dataset to regulators this year. If ITM-11 is approved, it would compete with Lutathera, which has been on the market since 2018 . Taking on a big pharma in a small indication is no small feat, particularly since ITM has no intention of partnering on the drug. Its strategy here will hinge partly on convincing doctors of the strength of the new data. “I strongly believe this will create a change in the way people practice medicine and the treatment of neuroendocrine tumors,” Cavey said, citing conversations ITM has had with physicians. The other main aspects of its commercial approach involve helping to boost access to radiopharmaceuticals, including improving its ordering system and supply infrastructure. Cavey says it can be difficult to coordinate the arrival of both the patient and the radiopharmaceutical at a hospital at the same time. ITM should also be able to sidestep the isotope manufacturing issues that have bedeviled both Novartis and Bristol Myers Squibb . It is the only company with both a therapeutic pipeline and in-house isotope production. “Our radioisotope business is about $200 million now and growing,” Cavey said, and the company has “heavily invested” in ytterbium-161 as a potential new therapeutic isotope. All of which could make ITM an attractive takeover target, like Point Biopharma , RayzeBio and Fusion Pharmaceuticals . But Cavey insists the private company is not interested in a buyout. However, the company will “absolutely” be looking for opportunities to in-license assets, he said. Editor’s note: This article was updated to state that patients with pancreatic tumors were excluded from Novartis’ NETTER-1 study.

Clinical ResultPhase 3

100 Deals associated with Lutetium Dotatate LU-177

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	V10XX04	DB13985

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Neuroendocrine Tumors	Canada	Advanced Accelerator Applications USA, Inc.	09 Jan 2019
Gastro-Enteropancreatic Neuroendocrine Tumor	United States	Advanced Accelerator Applications USA, Inc.	26 Jan 2018
SSTR positive Gastro-Enteropancreatic Neuroendocrine Tumor	European Union	Advanced Accelerator Applications SA	26 Sep 2017
SSTR positive Gastro-Enteropancreatic Neuroendocrine Tumor	Iceland	Advanced Accelerator Applications SA	26 Sep 2017
SSTR positive Gastro-Enteropancreatic Neuroendocrine Tumor	Liechtenstein	Advanced Accelerator Applications SA	26 Sep 2017
SSTR positive Gastro-Enteropancreatic Neuroendocrine Tumor	Norway	Advanced Accelerator Applications SA	26 Sep 2017

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Advanced Neuroendocrine Neoplasm	Phase 3	China	Sinotau Pharmaceutical Group	01 Jun 2024
Advanced Pancreatic Neuroendocrine Tumor	Phase 3	China	Jiangsu Hengrui Pharmaceuticals Co., Ltd.	06 Jul 2023
Carcinoid Tumors, Intestinal	Phase 3	United States	Advanced Accelerator Applications SA	06 Sep 2012
Carcinoid Tumors, Intestinal	Phase 3	Belgium	Advanced Accelerator Applications SA	06 Sep 2012
Carcinoid Tumors, Intestinal	Phase 3	France	Advanced Accelerator Applications SA	06 Sep 2012
Carcinoid Tumors, Intestinal	Phase 3	Germany	Advanced Accelerator Applications SA	06 Sep 2012
Carcinoid Tumors, Intestinal	Phase 3	Italy	Advanced Accelerator Applications SA	06 Sep 2012
Carcinoid Tumors, Intestinal	Phase 3	Portugal	Advanced Accelerator Applications SA	06 Sep 2012
Carcinoid Tumors, Intestinal	Phase 3	Spain	Advanced Accelerator Applications SA	06 Sep 2012
Carcinoid Tumors, Intestinal	Phase 3	United Kingdom	Advanced Accelerator Applications SA	06 Sep 2012

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03972488 (NETTER-2, CTgov)	Phase 3	Gastro-Enteropancreatic Neuroendocrine Tumor	226	30 mg Octreotide long acting repeatable (LAR) (Sandostatin LAR Depot)+2.5% Lys-Arg sterile amino acid solution+Lutathera (Lutathera® Plus Octreotide LAR 30 mg (Investigational Arm))	qdsuwcmufi(nmzdwgisvy) = fbiipgygmn chiabgrtvk (uquntcjkav, wllnkrvkcy - nurhpowlxf) View more	-	10 Oct 2024
				High dose 60 mg octreotide long-acting repeatable (Octreotide LAR 60 mg (Control Arm))	qdsuwcmufi(nmzdwgisvy) = nqwxiwsrcj chiabgrtvk (uquntcjkav, cwtjvkkqza - vxnsnpowtp) View more
ASTRO2024	Phase 2	Meningioma somatostatin receptors	20	177Lu-Dotatate 7.4 GBq	kkmqcihmrz(emcvnqkatp) = zfosrnckro mcvmpegnkc (lajqtoqxwk, 52 - 94) View more	Positive	01 Oct 2024
ASTRO2024	Phase 2	Neuroendocrine Tumors	195	177 Lu-DOTATATE (177Lu-D >880 mCi)	giunksagzb(qelkgzfrhx) = wjybioonxz gyvwyldovv (qmjbxzxbar, 90 - 100) View more	Negative	01 Oct 2024
				177 Lu-DOTATATE (177Lu-D 800 Â± 10%)	giunksagzb(qelkgzfrhx) = omlphmcjrl gyvwyldovv (qmjbxzxbar, 73 - 100) View more
ASTRO2024	Not Applicable	Gastro-Enteropancreatic Neuroendocrine Tumor	-	<sup>177</sup>Lu-DOTATATE	ehbkadehtj(dbjsrinsrw) = ewjfarzaii ycsfcsajmj (insjmhemqj )	-	01 Oct 2024
NCT02743741 (OZM-067, ASTRO2024)	Not Applicable	-	33	177Lu-DOTATATE	ljnpivsbaf(bzwkhxkjqq) = eijgiikxzz ccdkpugxaf (avtbpkmrob, 0.87) View more	Positive	01 Oct 2024
				68Ga-DOTATATE	ljnpivsbaf(bzwkhxkjqq) = bxxmkkkwmw ccdkpugxaf (avtbpkmrob, 0.87) View more
Biospace Manual	Phase 2	Meningioma	20	Lutathera	sealcsgvdy(rhjoixvxbk) = diisdnxdbm adziitaizj (ysqtaifdjn ) View more	Positive	30 Sep 2024
NCT02743741 (OZM-067, EANM2024)	Not Applicable	-	173	Lu-DOTATATE (3-parameter bi-exponential (3PBE) fitting)	pjvjfifihp(srjsowzamz) = egymkgxpuo vtgdlbxfff (ojrsmljmdr, 0.77)	Positive	27 Sep 2024
				Lu-DOTATATE (Mono-exponential (ME) fitting)	pjvjfifihp(srjsowzamz) = xgnvrikrbv vtgdlbxfff (ojrsmljmdr, 0.77)
EANM2024	Not Applicable	Gastrointestinal Neoplasms	36	[177Lu]Lu-DOTA-TATE (Ileal NET)	lwrnhnlgcu(alnrrrbetp) = hqbjwkpecu feenhtutmi (mbalfvprqv ) View more	Positive	27 Sep 2024
Lu-177 DOTATATE (EANM2024)	Not Applicable	Paraganglioma \| Pheochromocytoma increased somatostatin receptor (SSTR) expression	26	2-4 courses of Lu-177 DOTATATE	jpiajjhcli(kkelvgmkyd) = nwwaqiempj drgnbietdz (avuuwylylx ) View more	Positive	27 Sep 2024
				≥5 courses of Lu-177 DOTATATE	feznvgrzth(jiglgiiwkm) = fuvgonxvez aufyinxnqu (biwadqyixa ) View more
EANM2024	Not Applicable	Neuroendocrine Tumors	-	[177Lu]- DOTA-TATE	eupiswjrxe(hwenbntjji) = RR-PRRT-associated AEs (grade 3-4) included thrombocytopenia (12.9%), lymphopenia (9.7%), anemia (6.5%), and leukopenia (3.2%). Importantly, no nephrotoxicity was observed during RR-PRRT. vcbcrefshn (dovdkthtxp )	Positive	27 Sep 2024

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis